维普期刊资源整合服务平台（V6.5）

127篇 您的检索式：作者名="de Azambuja E"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	The17q12-q21amplicon:Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours显示文摘	Mano MS Rosa DD De Azambuja E	2007	Cancer Treat Rev2007，33，：	1
2	Trastuzumabfor patients with HER2 positive breast cancer: delivery,duration and combination therapies显示文摘	Pinto AC Ades F de Azambuja E ef af	2013	Breast2013，，2：	1
3	Dissecting the heterogeneity of triple-negative breast cancer显示文摘	Metzger-Filho O Tutt A de Azambuja E	2012	J Clin Oncol2012，30，15：	1
4	Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation显示文摘	Lothaire P de Azambuja E Dequanter D	2006	Head Neck2006，28，3：	1
5	Targeting the PI3K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatmem of breast cancer显示文摘	Saini K S Loi S de Azambuja E	2013	Cancer Treat Rev2013，39，8：	1
6	Trastuzumab for early breast cancer: current status and future directions 显示文摘	Dinh P de Azambuja E Piocart - Gebhart MJ	2007	Clin Adv Hematol Oncol2007，5，9：	1
7	Review: side effects of approved molecular targeted therapies in solid cancers显示文摘	Widakowich C de Castro G Jr de Azambuja E	2007	Oncologist2007，12，12：	1
8	Ki-67 as a prog- nostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients 显示文摘	de Azambuja E Cardoso F de Casrto G Jr	2007	Br J Cancer2007，96，10：	1
9	Angiogenesis and cancer: a cross-talk between basic science and clinical trials ( the “do ut des” paradigm) 显示文摘	de Castro Junior G Puglisi F de Azambuja E	2006	Crit Rev Oncol Hematol2006，59，：	1
10	Dissecting the heterogeneity of triple-negative breast cancer显示文摘	Metzger-Filho O Tutt A de Azambuja E	2012	J Clin Oncol2012，30，15：	1
11	Trastuzumab for early breast cancer: current status and future directions显示文摘	Dinh P de Azambuja E Piccart-Gebhart MJ	2007	Clin Adv tte- matol Oncol2007，5，9：	1
12	Lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoALTYO) : Survival outcomes of a raudomised, open- label, multiceutre, phase 3 trim and their association with pathological complete response 显示文摘	de Azambuja E Holmes AP Piccart-Gebhart M	2014	Lancet Oncol2014，15，10：	1
13	Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients 显示文摘	de Azambuja E Cardoso F de Castro G Jr	2007	Br J Cancer2007，96，10：	1
14	Dissec- ting the heterogeneity of triple-negative breast cancer显示文摘	Metzger-Filho O Tutt A de Azambuja E	2012	J Clin Oncol2012，30，15：	1
15	Ki- 67 asprognostic marker in early breast cancer: a meta- analysis ofpublished studies involving 12,155 patients显示文摘	de Azambuja E Cardoso F de Castro G Jr	2007	Br J Cancer2007，96，10：	1
16	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer显示文摘	Saini KS Loi S de Azambuja E	2013	Cancer Treat Rev2013，39，8：	1
17	Targeting the PI3 K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer显示文摘	Saini KS Loi S de Azambuja E	2013	Cancer Treat Rev2013，39，8：	1
18	The 17q12 - q21 amplicon: Her2 and topoisomerase-Ⅱalpha and their importance to the biology of solid tttmours 显示文摘	Mano MS Rosa DD De Azambuja E	2007	Cancer Treat Rev2007，33，1：	1
19	Ki- 67 as prognostic marker in early breast cancer: a meta- analysis of published studies involving 12,155 patients 显示文摘	de Azambuja E Cardoso F de Castro G Jr	2007	BrJ Cancer2007，96，10：	1
20	Ki-67 as prognostic marker in early breast cancer:a meta-analysis of published studies involving 12,155 patients显示文摘	de Azambuja E Cardoso F de Castro G Jr et a1	2007	Br J Cancer2007，96，10：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示